Safety Commissioner highlights ‘injustice' over lack of redress for mesh scandal
Ministers have been urged to give financial compensation to women affected by the mesh scandal as the Patient Safety Commissioner expressing her disappointment over a lack of action to date.
Last year, Dr Henrietta Hughes highlighted that thousands of women's lives were 'destroyed' because of pelvic mesh and said that there was a 'clear case for redress' for thousands of women and children affected by vaginal mesh implants and sodium valproate.
She said the Government should create a two-stage financial redress scheme – an interim scheme and a main scheme.
But campaigners said they have 'faced silence' in the year since the report was published.
Dr Hughes said: 'It is very disappointing that women who have suffered so much harm are still waiting for redress.
'This is an injustice as it augments the original harm they suffered. They need redress now and the Government must act immediately.'
Kath Sansom, founder of the Sling the Mesh campaign group, called on the Government to urgently act on the report's findings.
Ms Sansom told the PA news agency that women's lives have been 'irreparably damaged' by mesh, with many unable to work or reduce their hours due to chronic pain and disability.
But despite this, no compensation scheme has been put in place to help those affected, Ms Sansom said.
She said: 'For a year, we have waited for action, but all we've received is silence.
'The Hughes Report made it clear that financial redress is essential.
'It is unacceptable that the Government continues to turn a blind eye to women who have lost their health, their jobs, and their quality of life through no fault of their own.
'The time for excuses is over – we need action now.'
Transvaginal mesh implants were used to treat pelvic organ prolapse and incontinence after childbirth.
However, in some cases they have caused debilitating harm to some women.
This morning's launch in Parliament of my report into redress options for those harmed by pelvic mesh and valproate heard how women were deceived, kept in the dark, and fobbed off and let down by the health system – read the report at https://t.co/o02LyUM9RM pic.twitter.com/ZQXEPmt8Fu
— Patient Safety Commissioner (@PSCommissioner) February 7, 2024
Side effects have included infection, pelvic pain, difficulty urinating, pain during sex and incontinence.
MP Sharon Hodgson, chairwoman of the All-Party Parliamentary Group for First Do Harm, said: 'A year on from the publication of the Hughes Report which calls for a redress scheme for women impacted by the mesh and valproate scandals – the Government are yet to issue a response.
'I will not rest until these thousands of women and families get the justice they deserve.
'They have been let down by a system supposed to protect them and as a result will suffer lifelong physical and mental barriers – they will never be the same again.
'While financial compensation cannot reverse this damage, it would at least provide confirmation to them that – contrary to the gaslighting and dismissal they have received – they were right to raise concerns, that they were wronged, that it wasn't their fault, and that they deserve better.'
Alison Fuller, from the charity Epilepsy Action, said: 'It's been a year since Hughes report led by the Patient Safety Commissioner on redress options for people harmed by sodium valproate and pelvic mesh.
'For the first time, the report sets out the options to provide redress for people harmed by sodium valproate, when risks weren't communicated effectively.
'These families are struggling immensely, not just from an emotional standpoint, but from a financial one, too. They have been for decades. They simply can't wait any longer.
'Yet a year on we still have no clear timeline for a response to the recommendations. We're aware the Government has acknowledged it and committed to considering it. But the people affected deserve more than that.'
A Department of Health and Social Care spokesperson said: 'The harm caused by sodium valproate and pelvic mesh continues to be felt today. Our sympathies are with those affected and we are fully focused on how best to support patients and prevent future harm.
'This is a complex area of work and Health Minister Baroness Gillian Merron met with some of those affected before Christmas, and has committed to providing an update to the Patient Safety Commissioner at the earliest opportunity.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
5 hours ago
- Bloomberg
RFK Jr. Says He Won't Put Anti-Vaxxers on Key Vaccine Panel
Health Secretary Robert F. Kennedy Jr. pledged to bring in 'highly credentialed physicians' and 'not anti-vaxxers' to fill newly vacant slots on an influential committee that advises the US government on vaccine policy. Kennedy made the remarks roughly 24 hours after he abruptly dismissed all 17 members of the Advisory Committee on Immunization Practices in an unprecedented move he said was needed to restore public confidence in vaccine science. The new members will be in place before the panel's next scheduled meeting that starts June 25, Kennedy said Tuesday.
News24
18 hours ago
- News24
Graphs that paint the picture of HIV in SA: Part 2
Eight million people living with HIV. Just over 6 million on treatment. Behind these big numbers lurk a universe of fascinating epidemiological dynamics. In this special briefing, Spotlight editor Marcus Low unpacks what we know about the state of HIV in South Africa. This is part 2 of 3. In Part 1 of this Spotlight special briefing, we looked at some of the big picture dynamics of HIV in South Africa. Most of the news there was good. In Part 2, however, we look at why making progress is getting harder and consider some key vulnerabilities of our HIV programme. The final 10% or 20% will be the hardest Spotlight The above graph shows the number of people starting treatment by year. As you can see, around a decade ago, this number was often higher than 500 000. Since 2021, it has been below 300 000. Government could no doubt do a better job at helping people start and stay on treatment, but there are also good epidemiological reasons for the slow-down. In short, those who were sicker or more eager to start treatment - and for whom taking treatment is relatively easy - are mostly already on treatment. Those who are not on treatment are likely less motivated to take treatment or may have challenges in their lives that make it hard for them to start and stay on treatment. Convincing and supporting this latter group to start and stay on treatment is quite simply harder than it is for the prior group, but it is where the focus will have to be if we are to get our numbers higher. It is one reason why many are so concerned about recent aid cuts that have disproportionately impacted HIV services for marginalised groups like sex workers, people who use drugs, and men who have sex with men. These groups of people often feel unwelcome at public sector clinics. One key thing to keep in mind when looking at HIV numbers is that people cycle in and out of HIV treatment a lot. A misleading impression can, for example, be created if one looks at the number of people starting or restarting treatment without subtracting the number of people who have stopped taking treatment over the same period. It is for this reason that it is best to focus mainly on the total number of people on treatment and how that number changes from year to year (you can see a graph of this in Part 1 of this series). Finally, another important nuance in the numbers is how much damage has been done to people's immune systems by the time they start treatment – the earlier you start, the better your long-term prognosis. It is concerning that, of the 241 000 people who started treatment in 2023/2024, 54 000 had CD4 counts below 200 cells per cubic millimetre, an indication that their immune systems had already been hit hard. Bigger programme, bigger vulnerabilities? Much of how an epidemic grows or wanes depends on how many people are infectious at a specific point in time. Generally, the more infectious people there are in a population, the more other people will get infected. It follows that, if you can't cure people, the next best thing from an epidemiological control perspective, is to make people non-infectious. (See our recent Special Briefing on the search for an HIV cure.) Fortunately, apart from keeping people healthy, consistently taking antiretroviral medicines also make the vast majority of people living with HIV non-infectious. Thus, while all eight million people living with HIV in South Africa could potentially become infectious, antiretroviral treatment means that only around two million of them actually are. Spotlight It is very unlikely that we will drop from 6.2 million people on treatment to 5.2, or even 5.5, but even just dropping by 100 000 or 200 000, will mean 100 000 or 200 000 more people become infectious. That would give our HIV epidemic a blast of oxygen it wouldn't have had otherwise. There are real vulnerabilities here. According to preliminary modelling that the Department of Health commissioned in response to US funding cuts, failure to replace the HIV services that were funded by the US in South Africa could result in an additional 150 000 to 295 000 additional infections by 2028. It will take a year or two before we see the actual impact of the aid cuts in data sources such as Thembisa, but, as reported by Daily Maverick, there have been some early indications from the country's public lab service that important numbers are down. *Check back tomorrow for Part 3 of this series. You can also find the complete version of this #InTheSpotlight special briefing as a single page on the Spotlight website. Note: All of the above graphs are based on outputs from version 4.8 of the Thembisa model published in March 2025. We thank the Thembisa team for sharing their outputs so freely. Graphs were produced by Spotlight using the R package ggplot2. You are free to reuse and republish the graphs. For ease of use, you can download them as a Microsoft PowerPoint slide deck. Technical note: The Thembisa model outputs include both stock and flow variables. This is why we have at some places written 2024 (for stock variables) and 2023/2024 (for flow variables). 2024 should be read as mid-2024. 2023/2024 should be read as the period from mid-2023 to mid-2024. Show Comments ()
Bloomberg
a day ago
- Bloomberg
RFK Jr. Removes All Members of CDC Panel Advising on Vaccines
The Department of Health and Human Services is retiring the 17 members of a committee of government vaccine advisers, Secretary Robert F. Kennedy Jr. said Monday. 'A clean sweep is needed to reestablish public confidence in vaccine science,' Kennedy said in an opinion piece published in the Wall Street Journal.
